Together for Short Lives
Call the Helpline 0808 8088 100

Reversal of morphine-induced urinary retention after methylnaltrexone

Journal title
Archives of disease in childhood. Fetal and neonatal edition
Publication year
2012
Author(s)
Garten, L.; Buhrer, C.
Pages
F151-3
Volume
97
Number
2

Methylnaltrexone, a peripherally acting micro-opioid receptor antagonist, has been studied in adults for the treatment of opioid-induced constipation in advanced illness. Here, the authors document the first neonate to receive methylnaltrexone in an attempt to resolve morphine-induced urinary retention. An asphyxiated term newborn infant underwent induced hypothermia and received morphine by continuous intravenous infusion. After 36 h, the patient developed progressive urinary retention (calculated bladder volume 63 ml), followed by venous congestion of the lower extremities. Attempted bladder catheterisation was unsuccessful. Voiding occurred within 20 min after intravenous administration of methylnaltrexone (0.15 mg/kg body weight). A relapse of urinary retention 24 h later responded well to a second dose of methylnaltrexone. There were no adverse effects and no opioid withdrawal symptoms. The neonate had normal findings in cranial MRI that was performed after elective cessation of induced hypothermia.

Research abstracts